CAMALLERGY

Camallergy (Cambridge Allergy Ltd) is a biopharmaceutical company dedicated to providing innovative, patient-centric treatments to address the millions of patients suffering worldwide from food allergies. Camallergy’s lead product, CA002, is a second-generation novel oral immunotherapy for the treatment of peanut allergy designed to offer “bite-proof” protection to patients within 14 weeks of therapy. The Company’s unique intellectual property and treatment regimen are based on the clinical work initiated at Cambridge University Hospitals NHS Foundation Trust in Cambridge, UK.
CAMALLERGY
Industry:
Biotechnology Clinical Trials Health Care Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.camallergy.com
Total Employee:
1+
Status:
Active
Total Funding:
1.92 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Global Site Tag Amazon Pound Sterling Typekit
Current Advisors List
Board_member
Current Employees Featured
Pamela Ewan Co-founder and Chief Medical Officer @ Camallergy
Co-founder and Chief Medical Officer
2015-01-01
Sherden Timmins Co-founder & Chief Operating Officer @ Camallergy
Co-founder & Chief Operating Officer
2018-10-01
Andrew Clark Co-Founder and Chief Scientific Officer @ Camallergy
Co-Founder and Chief Scientific Officer
2015-12-01
Barry Saint Chief Financial Officer @ Camallergy
Chief Financial Officer
2019-01-01
Founder
Investors List
Innovate UK
Innovate UK investment in Grant - Camallergy
Jonathan Milne
Jonathan Milne investment in Angel Round - Camallergy
Official Site Inspections
http://www.camallergy.com
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013

More informations about "Camallergy"
About - Camallergy
Camallergy is developing a pipeline of products to treat food allergies, starting with peanut allergy. Peanut allergy: the highest priority. Peanut allergy is highly prevalent. It affects 1.4 to 3% of children and at least 0.5% of adults in high …See details»
Team — Camallergy
Mike represents Dr Jonathan Milner, PhD, who was Camallergy’s lead investor through its early stages. Jonathan is the founder of Abcam plc, and an experienced entrepreneur and investor. …See details»
Camallergy - Crunchbase Company Profile & Funding
Camallergy’s lead product is a novel oral immunotherapy for the treatment of peanut allergy designed to offer “bite-proof” protection to patients within 14 weeks of therapy. The Company’s unique intellectual property and treatment …See details»
Camallergy - LinkedIn
Camallergy | 594 followers on LinkedIn. Developing life-changing treatments for food allergy | Millions of people suffer from food allergy. We develop pioneering treatments so they can live …See details»
Camallergy Inc - Crunchbase Company Profile & Funding
Camallergy Inc . Connect to CRM . Save . Summary. People. Technology. Signals & News. About. ... Recent News & Activity. There is no recent news or activity for this profile. Details. …See details»
Camallergy Company Profile: Overview and Full News Analysis
Camallergy, a company based in England, is dedicated to addressing the significant issue of food allergies that affect millions of people worldwide. They specialize in developing innovative …See details»
Camallergy - Contacts, Employees, Board Members, Advisors
Organization. Camallergy . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. ... Camallergy has 3 …See details»
Camallergy - VentureRadar
Camallergy’s lead product, CA002, is a novel oral immunotherapy for the treatment of peanut allergy designed to offer “bite-proof” protection to patients within 14 weeks of therapy. The …See details»
Camallergy Company Profile 2025: Valuation, Funding …
Camallergy General Information Description. Developer of an oral immunotherapy drug intended to focus on food allergies. The company's drug is a patient-centric treatment of peanut allergies designed to offer "bite-proof" …See details»
Cambridge Allergy - Overview, News & Similar companies
Camallergy is a biopharmaceutical company dedicated to providing innovative, patient-centric treatments to address the millions of people worldwide who suffer from food allergies. …See details»
Camallergy Overview | SignalHire Company Profile
Camallergy is a private company that has been in the industry for 9 years. The company currently specializes in the Pharmaceuticals area. The position of the CEO is occupied by Baxter …See details»
Technology — Camallergy
The safety and efficacy of the Camallergy’s treatments are subject to confirmation in phase 3 clinical trials. They are investigational and not yet approved by regulatory authorities. SubscribeSee details»
Camallergy - Products, Competitors, Financials, Employees, …
• CA002 (Camallergy): Camallergy is preparing its lead product, CA002 for the treatment of peanut allergy, for Phase III trials to support regulatory approval in the US and Europe CA002 …See details»
Camallergy - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Science — Camallergy
Camallergy’s approach: at-home up-dosing. Tiny, daily dose increments replace large, fortnightly dose increases. Removing large dose increases aims to reduce side effects. We aim to enable …See details»
Camallergy - Updates, News, Events, Signals & Triggers
Camallergy may be growing as it is listed among several companies in the context of peanut allergy pipeline analysis, which suggests active involvement in clinical trials and product …See details»
Living with Food Allergies - Caring & Prevention | FARE
1 day ago FARE (Food Allergy Research & Education) is a 501(c)(3) charitable organization with the mission to improve the quality of life and health of those with food allergy through …See details»
News & media - Camallergy
23.03.21 Camallergy awarded £1.1m funding under Innovate UK Biomedical Catalyst Award for novel peanut allergy treatment . 08.01.21 Camallergy’s UK-based manufacturing facility …See details»
Camallergy - Tech Stack, Apps, Patents & Trademarks - Crunchbase
The intellectual property of Camallergy includes 2 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Additionally, Camallergy has …See details»
Clinical trials - Camallergy
Early phase clinical trials. The phase 3 programme builds on the unprecedented results generated in our early phase clinical trials. STOP2 showed strong, clinically relevant results in children, …See details»